The second sensitivity analysis showed that, after additionally adjusting for antidepressant and anti-inflammatory drugs at wave 6, CRP remained a statistical mediator of the prospective association between excess body weight (overweight + obesity) and elevated somatic symptoms, explaining a total of 15.16% (indirect effect: β = 0.003, 95% CI: 0.001, 0.006) (Supplementary Table S5 and Fig. S1). The gene discussed is CRP; the disease is obesity disorder.